FDA Alerts
FDA: Blood Pressure Medication Warning
The U.S. Food and Drug Administration (FDA) is warning of possible risks when using blood pressure medicines containing aliskiren with other drugs called angiotensin converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) in patients with diabetes or kidney (renal) impairment.
FDA Drug Safety Communication: Tekturna
The U.S. Food and Drug Administration (FDA) is warning of possible risks when using blood pressure medicines containing aliskiren with other drugs called angiotensin converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) in patients with diabetes or kidney (renal) impairment.
Risk of Blood Clots Associated With Birth Control
The U.S. Food and Drug Administration (FDA) has completed its review of recent observational ( epidemiologic ) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills.
Celexa and Risk of Arrhythmia
The U.S. Food and Drug Administration (FDA) is clarifying dosing and warning recommendations for the antidepressant Celexa ( citalopram hydrobromide ; also available in generic form).
FDA Announces Safety Changes In Labeling For Some Cholesterol-lowering Drugs
Important safety changes to the labeling for some widely used cholesterol-lowering drugs known as statins are being announced today by the U.S. Food and Drug Administration.
These products, when used with diet and exercise, help to lower a person’s “bad” cholesterol (low-density lipoprotein cholesterol). The products include: Lipitor ( atorvastatin ), Lescol ( fluvastatin ), Mevacor ( lovastatin ), Altoprev ( lovastatin extended-release), Livalo ( pitavastatin ), Pravachol ( pravastatin ), Crestor ( rosuvastatin ), and Zocor ( simvastatin ). Combination products include: Advicor (...
FDA approves Firazyr
The U.S. Food and Drug Administration today approved Firazyr ( icatibant ) Injection for the treatment of acute attacks of a rare condition called hereditary angioedema ( HAE ) in people ages 18 years and older.
FDA Drug Safety Communication: Celexa
The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and patients that the antidepressant Celexa ( citalopram hydrobromide ; also marketed as generics) should no longer be used at doses greater than 40 mg per day because it can cause abnormal changes in the electrical activity of the heart. Studies did not show a benefit in the treatment of depression at doses higher than 40 mg per day.
FDA Drug Safety Communication: Celexa
The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and patients that the antidepressant Celexa ( citalopram hydrobromide ; also marketed as generics) should no longer be used at doses greater than 40 mg per day because it can cause abnormal changes in the electrical activity of the heart. Studies did not show a benefit in the treatment of depression at doses higher than 40 mg per day.
Previously, the citalopram drug label stated that certain patients may require a dose of 60 mg per day.
Facts about Celexa ( citalopram hydrobromide )
Is in a cla...
FDA Drug Safety Communication: Letairis
The U.S. Food and Drug Administration (FDA) is removing the warning related to liver injury from the boxed warning of the Letairis ( ambrisentan ) tablet label.
FDA Drug Safety Communication: Pradaxa
The U.S. Food and Drug Administration (FDA) is alerting the public to important storage and handling requirements for Pradaxa ( dabigatran etexilate mesylate ) capsules.